Illustris - header-01

Cutting-edge topical Drug Delivery Technology From Illustris. The Next Step in Re-Formulating Oral or Injectable Products into Topicals.

Illustris Pharmaceuticals, Inc., an important business partner of LGM Pharma, has developed a proprietary technology to enable the delivery of molecules (up to 160KD or greater) through tissue structures, optimizing the absorption of compounds typically delivered through the skin, eye and mucosal surfaces.

The unique Illustris technology creates opportunities to deliver active moieties in a unique manner, expanding opportunities for drug delivery while potentially providing enhanced safety and efficacy of a new array of products. The addition of the Illustris technology to your active ingredients or development projects can enhance efficacy, improve safety and provide a significant advantage to competitive barriers of entry, for both small molecule APIs and for large-molecule active ingredients (of at least 160KD) which are historically difficult or impossible to deliver topically.

Illustris is able to achieve this by significantly enhancing the penetration of active ingredients enabling you to reduce the previously required active ingredient concentrations in existing topical applications without sacrificing efficacy, convert oral or injectable compounds to topical applications and utilize Illustris’ composition of matter patents once issued.

 
 

Illustris Pharmaceuticals, Inc., an important business partner of LGM Pharma, has developed a proprietary technology to enable the delivery of molecules (up to 160KD or greater) through tissue structures, optimizing the absorption of compounds typically delivered through the skin, eye and mucosal surfaces.

The unique Illustris technology creates opportunities to deliver active moieties in a unique manner, expanding opportunities for drug delivery while potentially providing enhanced safety and efficacy of a new array of products. The addition of the Illustris technology to your active ingredients or development projects can enhance efficacy, improve safety and provide a significant advantage to competitive barriers of entry, for both small molecule APIs and for large-molecule active ingredients (of at least 160KD) which are historically difficult or impossible to deliver topically.

Illustris is able to achieve this by significantly enhancing the penetration of active ingredients enabling you to reduce the previously required active ingredient concentrations in existing topical applications without sacrificing efficacy, convert oral or injectable compounds to topical applications and utilize Illustris’ composition of matter patents once issued.

 
 

Illustris applies a novel approach to drug delivery by employing what it calls “decoys” that open a temporary portal into the tissue structure, creating a mechanism for delivery of molecules (up to 160KD or greater) to targeted tissue sites. Illustris can deploy the appropriate amount of decoy to fully penetrate or partially permeate the targeted tissue structure or organ system to enable specific targeted delivery to meet the clinical objectives envisioned for administration of the active ingredient.

Illustris’ proprietary technology was invented by Dr. Jacob Waugh, Founder, Chief Scientific Officer, Medical director and a member of the board of directors of Illustris. Dr. Waugh has nearly 30 years of experience in applied cross-disciplinary research. He trained with pioneering leaders in molecular medicine and chemistry, has received numerous awards, and has authored over 40 research manuscripts and publications. Dr. Waugh has also served as an advisor in the medical device and pharmaceutical industries as well as a reviewer for a number of prominent scientific and medical journals.

Illustris has filed broad patent applications across several classes of applications and compounds. We believe upon the conclusion of the appropriate studies, the Illustris family of technologies will provide a significant competitive advantage with its novel approach to molecule delivery yielding enhanced safety and efficacy for patients.

The Illustris technology has been tested in more than fifty molecules! For more information regarding Illustris, please visit their website at www.illustris.com or contact our business development team at LGM for further details.

Illustris applies a novel approach to drug delivery by employing what it calls “decoys” that open a temporary portal into the tissue structure, creating a mechanism for delivery of molecules (up to 160KD or greater) to targeted tissue sites. Illustris can deploy the appropriate amount of decoy to fully penetrate or partially permeate the targeted tissue structure or organ system to enable specific targeted delivery to meet the clinical objectives envisioned for administration of the active ingredient.

Illustris’ proprietary technology was invented by Dr. Jacob Waugh, Founder, Chief Scientific Officer, Medical director and a member of the board of directors of Illustris. Dr. Waugh has nearly 30 years of experience in applied cross-disciplinary research. He trained with pioneering leaders in molecular medicine and chemistry, has received numerous awards, and has authored over 40 research manuscripts and publications. Dr. Waugh has also served as an advisor in the medical device and pharmaceutical industries as well as a reviewer for a number of prominent scientific and medical journals.

Illustris has filed broad patent applications across several classes of applications and compounds. We believe upon the conclusion of the appropriate studies, the Illustris family of technologies will provide a significant competitive advantage with its novel approach to molecule delivery yielding enhanced safety and efficacy for patients.

The Illustris technology has been tested in more than fifty molecules! For more information regarding Illustris, please visit their website at www.illustris.com or contact our business development team at LGM for further details.

Other Featured Clients in Action

Orbis Biosciences, Inc. provides controlled-release delivery technologies to create revolutionary pharmaceutical products that are safer and more effective than existing treatment options. Learn More >


Orbis Biosciences, Inc. provides controlled-release delivery technologies to create revolutionary pharmaceutical products that are safer and more effective than existing treatment options. Learn More >

Opertech Bio is a service-based business offering its customers a pioneering approach to measuring taste, covering the food and beverage, flavor ingredients, pet food, and pharmaceutical industries. Learn More >

Opertech Bio is a service-based business offering its customers a pioneering approach to measuring taste, covering the food and beverage, flavor ingredients, pet food, and pharmaceutical industries. Learn More >

This website uses cookies. By using our site, you agree to our terms of service